Non-Cochrane · other · PM42801102
Analysis of Antibiotic Resistance Patterns and Distribution of Staphylococcus aureus in the Middle East: A Systematic Review and Meta-Analysis.
Alidadpour Sarina, Pakzad Reza, Ekvan Mohammad Hossein, et al. · The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026 · PubMed · doi:10.1155/cjid/2830917
Findings
128 findings
| Population | ||||
|---|---|---|---|---|
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to methicillin | None | MRSA prevalence Middle East and neighboring countries | Prevalence (%) 48.60 [44.59, 52.60] GRADE not reported 148 studies |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to methicillin | None | MRSA resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient -3.3900000000000004e-05 [-0.00010800000000000001, 4.02e-05] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to methicillin | None | MRSA resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient 0.014199999999999999 [-0.00189, 0.0302] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Middle East and neighboring countries | Prevalence (%) 2.67 [1.53, 4.05] GRADE not reported 157 studies |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Vancomycin | None | Vancomycin resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient -9.88e-06 [-4.8400000000000004e-05, 2.86e-05] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Vancomycin | None | Vancomycin resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient 0.00412 [-0.0061600000000000005, 0.0144] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Gentamicin | None | Gentamicin resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient 3.5000000000000004e-05 [-0.016, 0.0161] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Middle East and neighboring countries | Prevalence (%) 28.53 [24.45, 32.78] GRADE not reported 145 studies |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Gentamicin | None | Gentamicin resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient 2.09e-05 [-5.75e-05, 9.93e-05] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Erythromycin | None | Erythromycin resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient -0.009380000000000001 [-0.024900000000000002, 0.0061600000000000005] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Erythromycin | None | Erythromycin resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient 1.8e-06 [-6.49e-05, 6.85e-05] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Middle East and neighboring countries | Prevalence (%) 48.92 [45.32, 52.53] GRADE not reported 145 studies |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Clindamycin | None | Clindamycin resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient -6.55e-07 [-6.780000000000001e-05, 6.65e-05] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Middle East and neighboring countries | Prevalence (%) 34.51 [30.61, 38.51] GRADE not reported 153 studies |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Clindamycin | None | Clindamycin resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient -0.00613 [-0.022000000000000002, 0.00974] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient -0.0167 [-0.0332, -0.000127] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Middle East and neighboring countries | Prevalence (%) 34.01 [29.80, 38.34] GRADE not reported 150 studies |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient 1.99e-06 [-7.59e-05, 7.99e-05] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Middle East and neighboring countries | Prevalence (%) 26.42 [22.00, 31.08] GRADE not reported 143 studies |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to TMP/SMX | None | TMP/SMX resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient -2.92e-05 [-0.00011000000000000002, 5.1200000000000004e-05] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to TMP/SMX | None | TMP/SMX resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient 0.00562 [-0.0115, 0.0227] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Penicillin G | None | Penicillin G resistance association with sample size Middle East and neighboring countries | Meta-regression coefficient 3.24e-05 [-4.860000000000001e-05, 0.000113] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Penicillin G | None | Penicillin G resistance association with publication year Middle East and neighboring countries | Meta-regression coefficient 0.0101 [-0.004370000000000001, 0.0246] GRADE not reported Studies not reported |
| Human Staphylococcus aureus isolates in Middle East and neighboring countries | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Middle East and neighboring countries | Prevalence (%) 92.32 [89.73, 94.61] GRADE not reported 104 studies |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to methicillin | None | MRSA prevalence Iran · Iran | Prevalence (%) 49.89 [45.16, 54.62] GRADE not reported 86 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to methicillin | None | MRSA prevalence Afghanistan · Afghanistan | Prevalence (%) 43.84 [15.95, 74.00] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Cyprus | Susceptibility to methicillin | None | MRSA prevalence Cyprus · Cyprus | Prevalence (%) 40.53 [35.96, 45.24] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to methicillin | None | MRSA prevalence Egypt · Egypt | Prevalence (%) 59.22 [43.41, 74.16] GRADE not reported 12 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to methicillin | None | MRSA prevalence Iraq · Iraq | Prevalence (%) 70.19 [44.35, 90.70] GRADE not reported 10 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to methicillin | None | MRSA prevalence Israel · Israel | Prevalence (%) 41.16 [10.90, 75.70] GRADE not reported 4 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to methicillin | None | MRSA prevalence Jordan · Jordan | Prevalence (%) 47.92 [35.99, 59.97] GRADE not reported 5 studies |
| Human Staphylococcus aureus isolates in Kuwait | Susceptibility to methicillin | None | MRSA prevalence Kuwait · Kuwait | Prevalence (%) 55.09 [50.99, 59.15] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Lebanon | Susceptibility to methicillin | None | MRSA prevalence Lebanon · Lebanon | Prevalence (%) 34.85 [23.53, 47.58] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Oman | Susceptibility to methicillin | None | MRSA prevalence Oman · Oman | Prevalence (%) 23.81 [8.22, 47.17] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Pakistan | Susceptibility to methicillin | None | MRSA prevalence Pakistan · Pakistan | no estimate extracted No studies found 0 studies |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to methicillin | None | MRSA prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 42.72 [27.96, 58.15] GRADE not reported 13 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to methicillin | None | MRSA prevalence Turkey · Turkey | Prevalence (%) 22.78 [13.92, 33.00] GRADE not reported 10 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to methicillin | None | MRSA prevalence Yemen · Yemen | no estimate extracted No studies found 0 studies |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Iran · Iran | Prevalence (%) 1.21 [0.21, 2.73] GRADE not reported 83 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Afghanistan · Afghanistan | Prevalence (%) 0.00 [0.00, 0.95] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Cyprus | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Cyprus · Cyprus | Prevalence (%) 1.11 [0.36, 2.58] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Egypt · Egypt | Prevalence (%) 12.77 [1.73, 30.20] GRADE not reported 15 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Iraq · Iraq | Prevalence (%) 19.26 [6.04, 37.11] GRADE not reported 16 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Israel · Israel | Prevalence (%) 9.48 [0.28, 25.58] GRADE not reported 4 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Jordan · Jordan | Prevalence (%) 0.00 [0.00, 0.45] GRADE not reported 5 studies |
| Human Staphylococcus aureus isolates in Kuwait | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Kuwait · Kuwait | Prevalence (%) 0.00 [0.00, 0.26] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Lebanon | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Lebanon · Lebanon | Prevalence (%) 3.03 [0.37, 10.52] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Oman | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Oman · Oman | Prevalence (%) 0.00 [0.00, 16.11] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Pakistan | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Pakistan · Pakistan | Prevalence (%) 0.00 [0.00, 7.25] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 0.83 [0.06, 2.14] GRADE not reported 18 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Turkey · Turkey | Prevalence (%) 0.00 [0.00, 0.00] GRADE not reported 8 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to Vancomycin | None | Vancomycin resistance prevalence Yemen · Yemen | no estimate extracted No studies found 0 studies |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Iran · Iran | Prevalence (%) 26.82 [21.25, 32.77] GRADE not reported 75 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Afghanistan · Afghanistan | Prevalence (%) 32.27 [0.85, 79.32] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Cyprus | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Cyprus · Cyprus | Prevalence (%) 0.00 [0.00, 0.82] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Egypt · Egypt | Prevalence (%) 24.49 [10.70, 41.35] GRADE not reported 11 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Iraq · Iraq | Prevalence (%) 26.33 [10.72, 45.52] GRADE not reported 14 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Israel · Israel | Prevalence (%) 6.36 [0.00, 26.59] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Jordan · Jordan | Prevalence (%) 35.74 [16.28, 57.85] GRADE not reported 6 studies |
| Human Staphylococcus aureus isolates in Kuwait | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Kuwait · Kuwait | Prevalence (%) 3.39 [2.02, 5.08] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Lebanon | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Lebanon · Lebanon | Prevalence (%) 50.00 [37.43, 62.57] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Pakistan | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Pakistan · Pakistan | Prevalence (%) 6.12 [1.28, 16.87] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 32.09 [22.96, 41.95] GRADE not reported 19 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Turkey · Turkey | Prevalence (%) 56.66 [43.68, 69.21] GRADE not reported 8 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to Gentamicin | None | Gentamicin resistance prevalence Yemen · Yemen | Prevalence (%) 76.22 [62.46, 87.84] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Iran · Iran | Prevalence (%) 48.11 [41.82, 54.42] GRADE not reported 70 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Afghanistan · Afghanistan | Prevalence (%) 66.57 [52.06, 79.67] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Cyprus | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Cyprus · Cyprus | Prevalence (%) 26.73 [22.69, 31.08] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Egypt · Egypt | Prevalence (%) 39.16 [27.31, 51.64] GRADE not reported 12 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Iraq · Iraq | Prevalence (%) 52.39 [36.01, 68.53] GRADE not reported 16 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Israel · Israel | Prevalence (%) 55.51 [42.32, 68.33] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Jordan · Jordan | Prevalence (%) 46.39 [32.30, 60.77] GRADE not reported 6 studies |
| Human Staphylococcus aureus isolates in Kuwait | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Kuwait · Kuwait | Prevalence (%) 60.95 [56.91, 64.92] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Lebanon | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Lebanon · Lebanon | Prevalence (%) 81.82 [70.39, 90.24] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Oman | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Oman · Oman | Prevalence (%) 38.10 [18.11, 61.56] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Pakistan | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Pakistan · Pakistan | Prevalence (%) 24.49 [13.34, 38.87] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 48.97 [44.40, 53.55] GRADE not reported 18 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Turkey · Turkey | Prevalence (%) 51.82 [33.53, 69.86] GRADE not reported 10 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to Erythromycin | None | Erythromycin resistance prevalence Yemen · Yemen | Prevalence (%) 76.19 [52.83, 91.78] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Iran · Iran | Prevalence (%) 32.54 [27.03, 38.29] GRADE not reported 74 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Afghanistan · Afghanistan | Prevalence (%) 27.59 [3.25, 63.03] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Egypt · Egypt | Prevalence (%) 29.57 [19.61, 40.54] GRADE not reported 15 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Iraq · Iraq | Prevalence (%) 35.69 [24.20, 48.02] GRADE not reported 18 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Israel · Israel | Prevalence (%) 25.97 [5.46, 53.40] GRADE not reported 5 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Jordan · Jordan | Prevalence (%) 32.06 [20.42, 44.88] GRADE not reported 7 studies |
| Human Staphylococcus aureus isolates in Kuwait | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Kuwait · Kuwait | Prevalence (%) 90.79 [88.26, 93.05] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Lebanon | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Lebanon · Lebanon | Prevalence (%) 50.00 [37.43, 62.57] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Oman | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Oman · Oman | Prevalence (%) 38.10 [18.11, 61.56] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Pakistan | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Pakistan · Pakistan | Prevalence (%) 22.45 [11.77, 36.62] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 39.19 [32.14, 46.46] GRADE not reported 17 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Turkey · Turkey | Prevalence (%) 43.26 [27.74, 59.46] GRADE not reported 8 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to Clindamycin | None | Clindamycin resistance prevalence Yemen · Yemen | Prevalence (%) 61.90 [38.44, 81.89] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Iran · Iran | Prevalence (%) 33.22 [26.85, 39.90] GRADE not reported 78 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Afghanistan · Afghanistan | Prevalence (%) 48.34 [16.63, 80.80] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Cyprus | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Cyprus · Cyprus | Prevalence (%) 0.89 [0.24, 2.27] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Egypt · Egypt | Prevalence (%) 36.05 [20.83, 52.79] GRADE not reported 12 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Iraq · Iraq | Prevalence (%) 30.86 [20.81, 41.84] GRADE not reported 19 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Israel · Israel | Prevalence (%) 20.30 [5.11, 41.80] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Jordan · Jordan | Prevalence (%) 37.12 [19.85, 56.19] GRADE not reported 6 studies |
| Human Staphylococcus aureus isolates in Kuwait | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Kuwait · Kuwait | Prevalence (%) 57.02 [52.29, 61.65] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Pakistan | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Pakistan · Pakistan | Prevalence (%) 6.12 [1.28, 16.87] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 36.57 [27.34, 46.31] GRADE not reported 16 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Turkey · Turkey | Prevalence (%) 42.02 [15.05, 71.76] GRADE not reported 9 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to Ciprofloxacin | None | Ciprofloxacin resistance prevalence Yemen · Yemen | Prevalence (%) 71.43 [47.82, 88.72] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Iran · Iran | Prevalence (%) 25.47 [18.50, 33.10] GRADE not reported 75 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Afghanistan · Afghanistan | Prevalence (%) 35.78 [28.17, 43.75] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Cyprus | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Cyprus · Cyprus | Prevalence (%) 59.91 [55.21, 64.48] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Egypt · Egypt | Prevalence (%) 38.07 [16.74, 61.99] GRADE not reported 13 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Iraq · Iraq | Prevalence (%) 21.00 [13.32, 29.76] GRADE not reported 16 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Israel · Israel | Prevalence (%) 30.27 [5.86, 61.85] GRADE not reported 4 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Jordan · Jordan | Prevalence (%) 20.59 [6.37, 39.75] GRADE not reported 5 studies |
| Human Staphylococcus aureus isolates in Kuwait | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Kuwait · Kuwait | Prevalence (%) 41.56 [37.54, 45.63] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Lebanon | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Lebanon · Lebanon | Prevalence (%) 6.06 [1.68, 14.80] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Oman | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Oman · Oman | Prevalence (%) 4.76 [0.12, 23.82] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 19.21 [10.89, 29.13] GRADE not reported 14 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Turkey · Turkey | Prevalence (%) 27.37 [18.98, 36.61] GRADE not reported 8 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to TMP/SMX | None | TMP/SMX resistance prevalence Yemen · Yemen | Prevalence (%) 73.71 [59.66, 85.82] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Iran | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Iran · Iran | Prevalence (%) 90.76 [86.56, 94.30] GRADE not reported 52 studies |
| Human Staphylococcus aureus isolates in Afghanistan | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Afghanistan · Afghanistan | Prevalence (%) 95.84 [87.05, 99.99] GRADE not reported 3 studies |
| Human Staphylococcus aureus isolates in Egypt | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Egypt · Egypt | Prevalence (%) 96.01 [90.01, 99.61] GRADE not reported 13 studies |
| Human Staphylococcus aureus isolates in Iraq | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Iraq · Iraq | Prevalence (%) 94.66 [89.51, 98.38] GRADE not reported 9 studies |
| Human Staphylococcus aureus isolates in Israel | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Israel · Israel | Prevalence (%) 100 [99.85, 100.00] GRADE not reported 2 studies |
| Human Staphylococcus aureus isolates in Jordan | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Jordan · Jordan | Prevalence (%) 73.09 [37.16, 97.54] GRADE not reported 5 studies |
| Human Staphylococcus aureus isolates in Lebanon | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Lebanon · Lebanon | Prevalence (%) 84.85 [73.90, 92.49] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Pakistan | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Pakistan · Pakistan | Prevalence (%) 97.96 [89.15, 99.95] GRADE not reported 1 study |
| Human Staphylococcus aureus isolates in Saudi Arabia | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Saudi Arabia · Saudi Arabia | Prevalence (%) 96.49 [93.77, 98.53] GRADE not reported 12 studies |
| Human Staphylococcus aureus isolates in Turkey | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Turkey · Turkey | Prevalence (%) 90.04 [55.42, 100.00] GRADE not reported 5 studies |
| Human Staphylococcus aureus isolates in Yemen | Susceptibility to Penicillin G | None | Penicillin G resistance prevalence Yemen · Yemen | Prevalence (%) 89.14 [77.88, 97.10] GRADE not reported 2 studies |
Included primary studies 219
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Sulayyim 2024 [Tumor induction in mice treated with hydrocortisone and innoculated with polyoma transformed hamster cells]. PMID:202419 | 1977 | 3 other reviews | not stated | not extracted yet |
| Ahmed 2023 matched by author and year (probable) | NR | 1 other review | not stated | not extracted yet |
| Akrami 2023 Studies on the regulatory properties of chloroplast fructose-1,6-bisphosphatase. PMID:202319 | 1978 | 1 other review | not stated | not extracted yet |
| Akrami et al 2023 Pig kidney phosphofructokinase. Purification to homogeneity and qualitative basic characterization. PMID:192023 | 1976 | 1 other review | not stated | not extracted yet |
| Alharbi 2022 matched by author and year (probable) | NR | 1 other review | not stated | not extracted yet |
| M'Aiber 2022 The lipid hypothesis. Pathophysiological basis. PMID:202220 | 1978 | 1 other review | not stated | not extracted yet |
| Taleb 2022 matched by author and year (probable) | NR | 1 other review | not stated | not extracted yet |
| Aal-Aaboda 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Abbasi Montazeri 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Abd-Elmonsef 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Abdul-Hasan 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Abdulmanea 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Abroo 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Abukhalil 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Abulreesh 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Addas 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Afhami 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Afsharian 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Afsharipour 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ahmadi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ahmadkhosravi 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ahmadrajabi 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ahmed 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ahrabi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Aktas 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al Balawi 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al Habsi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al Wutayd 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al Yousef 2016 A review on the effects of supercritical carbon dioxide on enzyme activity. PMID:20162013 | 2010 | this review only | not stated | not extracted yet |
| Al Yousef et al 2016 Pre- and postimplantation development of swine-cloned embryos derived from fibroblasts and bone marrow cells after inhibition of histone… PMID:20132016 | 2010 | this review only | not stated | not extracted yet |
| Al Zebary 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Amery 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Badaii 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Dhaheri 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Khfaji 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Mayahie 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Naqshbandi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Qaisi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Saadi 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Salihi 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Al-Sweih 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alahmadi 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alam 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Aldasouqi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alfeky 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alhhazmi 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alhubail 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alhumaid 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alikhani 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Aljeldah 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Almehdar 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Almuhayawi 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alsohaim 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Alzoubi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Amini 2023 How best to quantify soil seed banks in arid rangelands of the Nama Karoo? PMID:20238239 | 2011 | this review only | not stated | not extracted yet |
| Amini et al 2023 PMID:82392023 | NR | this review only | not stated | not extracted yet |
| Amirmozafari 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Anwar 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Arabestani 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Arikan 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ariyarad 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Armin 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Asadpour 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Assar 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Azimirad 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Aziz 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Azzab 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Baddal 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Badulla 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Banawas 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Behnod 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Bijari 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Bin Hameed 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Bostanmaneshrad 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Darban-Sarokhalil 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Dargahi 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Dehghani 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Demir 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Dianatkhah 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Dizji 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ebrahim-Saraie 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| El Aila 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| El Aila 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| El-Ameir 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| El-Aziz 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| El-Sokkary 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Elnasser 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Elsayed 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Emamie 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Fakheri 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Fasihi 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Fily 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Firoozeh 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Gaballah 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ghaima 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ghavghani 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Gordon 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Goudarzi 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Goudarzi 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Goudarzi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Goudarzi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Goudarzi 2020 Cross-sectional area of the elephant corpus callosum: comparison to other eutherian mammals. PMID:20206234 | 2010 | this review only | not stated | not extracted yet |
| Goudarzi et al 2020 PMID:62342020 | NR | this review only | not stated | not extracted yet |
| Guclu 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Haghighifar 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hamad 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hamishehkar 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hanon 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Haseeb 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hashemizadeh 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hassan 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hassanzadeh 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hesari 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hosseini 2020 Characterization of high density lipoproteins in human cholestasis. PMID:202013 | 1977 | this review only | not stated | not extracted yet |
| Hosseini et al 2020 [The Darmstadt Dermatologists' Evening. Conference at the lecture room of Merck AG, Darmstadt March 5, 1975]. PMID:132020 | 1975 | this review only | not stated | not extracted yet |
| Houri 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Imani Fooladi 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Imeni 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ismael 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Jahangir 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Javdan 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Johargy 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Kadkhoda 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Karbuz 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Karimi 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Karimzadeh 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Keihanian 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Khalaf 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Khalid 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Khalili 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Khasawneh 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Kishk 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Kodori 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| M'Aiber et al 2022 Assembly of type C oncornaviruses: a model. PMID:202022 | 1978 | this review only | not stated | not extracted yet |
| Mahdi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mahmoud 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mahmoudi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Malek 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Maleki 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Masihinejad 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Masoudifar 2021 Elevated expression of PGR5 and NDH-H in bundle sheath chloroplasts in C4 flaveria species. PMID:20212018 | 2010 | this review only | not stated | not extracted yet |
| Masoudifar et al 2021 Can nutrients prevent or delay onset of Alzheimer's disease? PMID:20182021 | 2010 | this review only | not stated | not extracted yet |
| Mataj 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Matalka 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mazloomi Nobandegani 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mazloomirad 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mirzaei 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Moawad 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mobasherizadeh 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Moghadam 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Moghaddam 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mohammadi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mostafa 2015 [Hormonal action and cyclic nucleotides]. PMID:201512 | 1976 | this review only | not stated | not extracted yet |
| Mostafa et al 2015 [Effects of the parenteral administration of trinitroglycerin on myocardial function, coronary flow and myocardial oxygen consumption in… PMID:122015 | 1979 | this review only | not stated | not extracted yet |
| Mostafavi 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Motamedi 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Motamedifar 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Naderi 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Naimi 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Naimi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Naimi 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Navidinia 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Navidinia 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Nouri 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Oguzkaya-Artan 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Oksuz 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Omid 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Omidifar 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Omran 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Orlin 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Owais 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Pakasticali 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Parastan 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Parhizgari 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Pezeshki Najafabadi 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Pourakbari 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Qodrati 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Radfar 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rasheed 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rasmi 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rezaee 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rezaei 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rezai 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rimaz 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Sadat 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Sadeghi Asl 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Saedi 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Salarvand 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Salloum 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Samanipour 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Selim 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Selim 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Shaaban 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Shahin 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Shahmohammadi 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Shamakhteh 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Sıpahı 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Soleymanzadeh-Moghadam 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Solgi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Soltani 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Sulayyim et al 2024 [The interaction of the betalipoproteins of plasma with the arterial wall in the etiopathogenie of the atherosclerosis (author's transl)]. PMID:192024 | 1976 | this review only | not stated | not extracted yet |
| Sultan 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Tabandeh 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Tahmasebi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Tahmasebi 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Taki 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Tayebi 2021 Poverty and psychiatric status. Longitudinal evidence from the New Haven Epidemiologic Catchment Area study. PMID:2021300 | 1991 | this review only | not stated | not extracted yet |
| Tayebi et al 2021 Characterization of ecotropic murine leukemia viruses in SJL/J mice. PMID:3002021 | 1985 | this review only | not stated | not extracted yet |
| Thari 2024 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Valian 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Wani 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Yaghoobi 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Yaghoobi 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Yakut 2023 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Yardimci 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ying 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Zamanian 2021 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Zaniani 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ziasistani 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Staphylococcus aureus isolates from human samples in Middle Eastern and neighboring countries (Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Palestine, Cyprus, Egypt, Afghanistan, Pakistan); at least 10 isolates; excluding nonhuman or environmental samples and strain-specific studies | S. aureus isolates from 14 countries (n=217 studies; combined sample size over 32,090; Iran n=111, Iraq n=24) |
| Intervention | Not applicable (antimicrobial susceptibility testing) | Not applicable |
| Comparison | Not applicable | Not applicable |
| Outcomes | Antibiotic resistance rates of S. aureus by specific antibiotic (MRSA prevalence and resistance to commonly reported antibiotics) | MRSA prevalence (n=148), vancomycin (n=157), gentamicin (n=145), erythromycin (n=145), clindamycin (n=153), ciprofloxacin (n=150), TMP/SMX (n=143), penicillin G (n=104) resistance |
| Study designs | Cross-sectional or surveillance studies published in English | Cross-sectional or surveillance studies (n=217) |
| Timing | Publications from January 2015 to September 24, 2024 | Studies published 2015 to 2024 |